{"transactions":[{"id":1958407,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Performance Stock Unit","published_at":"2023-03-10T09:30:13.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":134567,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each performance-based restricted stock unit (\"PSU\") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each performance-based restricted stock unit (\"PSU\") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Each performance-based restricted stock unit (\"PSU\") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Each performance-based restricted stock unit (\"PSU\") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":134567},"source":{"system":"sec-edgar","filing":"0001209191-23-017720","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000120919123017720/doc4.xml","form_type":"4"}},{"id":1958406,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-03-10T09:30:13.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":204808,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"One-fourth of the options are scheduled to vest on April 15, 2023, and one-sixteenth of the options are scheduled to vest each quarter thereafter."}],"balance_after":0,"derivative":{"exercise_price":11.33,"expiration_date":"2032-04-14","underlying":"Common Shares","underlying_shares":204808},"source":{"system":"sec-edgar","filing":"0001209191-23-017720","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000120919123017720/doc4.xml","form_type":"4"}},{"id":1958405,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-03-10T09:30:13.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":208218,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"One-fourth of the options vested on April 15, 2022, and one-sixteenth of the options vest each quarter thereafter."}],"balance_after":0,"derivative":{"exercise_price":17.88,"expiration_date":"2031-04-14","underlying":"Common Shares","underlying_shares":208218},"source":{"system":"sec-edgar","filing":"0001209191-23-017720","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000120919123017720/doc4.xml","form_type":"4"}},{"id":1958404,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-03-10T09:30:13.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":306427,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-fourth of the options vested on January 15, 2022, and one-sixteenth of the options vest each quarter thereafter."}],"balance_after":0,"derivative":{"exercise_price":20.54,"expiration_date":"2031-01-14","underlying":"Common Shares","underlying_shares":306427},"source":{"system":"sec-edgar","filing":"0001209191-23-017720","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000120919123017720/doc4.xml","form_type":"4"}},{"id":1958403,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Common Shares","published_at":"2023-03-10T09:30:13.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":321924,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects restricted stock units (\"RSUs\").  Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-017720","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000120919123017720/doc4.xml","form_type":"4"}},{"id":1958402,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Common Shares","published_at":"2023-03-10T09:30:13.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":95675,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes (the \"Per Share Consideration\")."}],"balance_after":321924,"source":{"system":"sec-edgar","filing":"0001209191-23-017720","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000120919123017720/doc4.xml","form_type":"4"}},{"id":2049428,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Common Shares","published_at":"2023-01-20T16:34:02.000Z","date":"2023-01-18","kind":"sale","acquired":false,"shares":8037,"price":26.89,"value":216114.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I."}],"balance_after":417599,"source":{"system":"sec-edgar","filing":"0001209191-23-004282","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000120919123004282/doc4.xml","form_type":"4"}},{"id":2134039,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Common Shares","published_at":"2022-10-20T16:53:10.000Z","date":"2022-10-18","kind":"sale","acquired":false,"shares":11156,"price":25.2,"value":281131.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I."}],"balance_after":425636,"source":{"system":"sec-edgar","filing":"0001209191-22-054196","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000120919122054196/doc4.xml","form_type":"4"}},{"id":2204427,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Common Shares","published_at":"2022-07-20T16:36:06.000Z","date":"2022-07-18","kind":"sale","acquired":false,"shares":11164,"price":12.87,"value":143680.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I."}],"balance_after":436792,"source":{"system":"sec-edgar","filing":"0001209191-22-042688","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000120919122042688/doc4.xml","form_type":"4"}},{"id":2292540,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Common Shares","published_at":"2022-04-21T16:25:00.000Z","date":"2022-04-19","kind":"sale","acquired":false,"shares":24594,"price":10.45,"value":257007.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $10.41 to $10.48. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":447956,"source":{"system":"sec-edgar","filing":"0001209191-22-025170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000120919122025170/doc4.xml","form_type":"4"}},{"id":2294545,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-19T16:46:56.000Z","date":"2022-04-15","kind":"grant","acquired":true,"shares":204808,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4 of the common shares underlying this option vest on April 15, 2023, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":204808,"derivative":{"exercise_price":11.33,"expiration_date":"2032-04-14","underlying":"Common Shares","underlying_shares":204808},"source":{"system":"sec-edgar","filing":"0001209191-22-024784","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000120919122024784/doc4.xml","form_type":"4"}},{"id":2294544,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Common Shares","published_at":"2022-04-19T16:46:56.000Z","date":"2022-04-15","kind":"grant","acquired":true,"shares":134567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units (\"RSUs\") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 15, 2023, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":472550,"source":{"system":"sec-edgar","filing":"0001209191-22-024784","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000120919122024784/doc4.xml","form_type":"4"}},{"id":2428554,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Common Shares","published_at":"2022-01-21T16:08:04.000Z","date":"2022-01-19","kind":"sale","acquired":false,"shares":19882,"price":14.68,"value":291867.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I."}],"balance_after":337983,"source":{"system":"sec-edgar","filing":"0001209191-22-004396","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000120919122004396/doc4.xml","form_type":"4"}},{"id":2744784,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-19T16:13:56.000Z","date":"2021-04-15","kind":"grant","acquired":true,"shares":208218,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4 of the common shares underlying this option vest on April 15, 2022, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":208218,"derivative":{"exercise_price":17.88,"expiration_date":"2031-04-14","underlying":"Common Shares","underlying_shares":208218},"source":{"system":"sec-edgar","filing":"0001209191-21-027277","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000120919121027277/doc4.xml","form_type":"4"}},{"id":2744783,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Common Shares","published_at":"2021-04-19T16:13:56.000Z","date":"2021-04-15","kind":"grant","acquired":true,"shares":134789,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units (\"RSUs\") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 15, 2022, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":357865,"source":{"system":"sec-edgar","filing":"0001209191-21-027277","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000120919121027277/doc4.xml","form_type":"4"}},{"id":2901652,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-20T16:41:21.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":306427,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4 of the common shares underlying this option under the Myovant Sciences Ltd. 2020 Inducement Plan vest on January 15, 2022, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":306427,"derivative":{"exercise_price":20.54,"expiration_date":"2031-01-14","underlying":"Common Stock","underlying_shares":306427},"source":{"system":"sec-edgar","filing":"0001209191-21-004330","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000120919121004330/doc4.xml","form_type":"4"}},{"id":2901651,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Common Shares","published_at":"2021-01-20T16:41:21.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":223076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares are to be acquired upon the vesting of certain Restricted Stock Units (\"RSUs\") granted to the Reporting Person. The RSUs shall vest as follows: 1/4 of the common shares underlying this restricted stock unit award under the Myovant Sciences Ltd. 2020 Inducement Plan vest on January 15, 2022, and 1/16 of the common shares underlying this restricted stock unit award vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":223076,"source":{"system":"sec-edgar","filing":"0001209191-21-004330","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000120919121004330/doc4.xml","form_type":"4"}},{"id":3200243,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-03-19T21:19:02.000Z","date":"2020-03-17","kind":"grant","acquired":true,"shares":16533,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 17, 2024. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2015 Omnibus Incentive Compensation Plan (the \"Plan\"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 17, 2024. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2015 Omnibus Incentive Compensation Plan (the \"Plan\"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant."}],"balance_after":16533,"derivative":{"underlying":"Common Stock","underlying_shares":16533},"source":{"system":"sec-edgar","filing":"0001179110-20-004009","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000117911020004009/edgar.xml","form_type":"4"}},{"id":3200242,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-19T21:19:02.000Z","date":"2020-03-17","kind":"grant","acquired":true,"shares":53984,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 17, 2024."}],"balance_after":53984,"derivative":{"exercise_price":45.14,"expiration_date":"2030-03-16","underlying":"Common Stock","underlying_shares":53984},"source":{"system":"sec-edgar","filing":"0001179110-20-004009","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000117911020004009/edgar.xml","form_type":"4"}},{"id":3393448,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-10-15T16:42:42.000Z","date":"2019-10-10","kind":"grant","acquired":true,"shares":25813,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on October 10, 2023; provided, that the vesting of the option will be accelerated such that 100% of the option will become fully vested upon the achievement of certain clinical, operational, and/or other milestones (approved by the compensation committee) prior to, on, or about December 31, 2019."}],"balance_after":25813,"derivative":{"exercise_price":17.61,"expiration_date":"2029-10-09","underlying":"Common Stock","underlying_shares":25813},"source":{"system":"sec-edgar","filing":"0001179110-19-011011","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000117911019011011/edgar.xml","form_type":"4"}},{"id":3420263,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":115680,"kind":"person","name":"Marek David C","position":1,"cik":"0001556914","reported_name":"Marek David C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-09-06T19:01:25.000Z","date":"2019-09-04","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted stock options pursuant to the Issuer's 2015 Omnibus Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant and 75% in equal increments on a quarterly basis for three years thereafter."}],"balance_after":125000,"derivative":{"exercise_price":24.28,"expiration_date":"2029-09-04","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001104659-19-049141","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556914/000110465919049141/a4.xml","form_type":"4"}}]}